Literature DB >> 9137523

Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.

N Nagai1, H Ogata.   

Abstract

PURPOSE: The major pharmacokinetic parameters of unchanged cisplatin (CDDP) related to nephrotoxicity were evaluated in rats in vivo using a pharmacodynamic model.
METHODS: CDDP was administered according to various dosing schedules (single bolus, intermittent bolus, or continuous infusion). Unchanged CDDP in plasma and urine was quantified using high-performance liquid chromatography (HPLC). The pharmacokinetics were assessed by model-independent methods. The relationship between pharmacokinetics and BUN levels was evaluated using a sigmoid maximum response (Emax) model.
RESULTS: Unchanged CDDP showed linear pharmacokinetics after single bolus injections of 1 to 5 mg/kg CDDP. Nephrotoxicity was ameliorated following intermittent bolus injection (1 mg/kg per day for 5 days) and continuous infusions (over 2 and 3 h) of the same CDDP doses (5 mg/kg), although these dosing schedules did not change the area under the concentration-time curve (AUC), total clearance (Clt), urinary excretion of unchanged CDDP or kidney platinum levels significantly. The maximum BUN level, as a nephrotoxicity marker, showed dose-related increases after single bolus injection of 1 to 5 mg/kg CDDP and after 3-h infusion of 5 to 25 mg/kg. The pharmacodynamic relationship between the maximum BUN level and Cmax and between the maximum BUN level and AUC were apparently different between single bolus injection and 3-h infusion. The maximum BUN level was related to the AUC calculated by plasma concentrations of unchanged CDDP greater than the threshold level (AUC > Cmin), a relationship most successfully described by the signoid Emax model, regardless of CDDP dose and schedule. The plasma threshold level of unchanged CDDP was determined as 0.9 microgram Pt/ml in rats.
CONCLUSIONS: The present results substantiated the importance of C x T (AUC) value as an indicator of CDDP-induced nephrotoxicity in vivo as well as of tumor cell-killing effect of CDDP in vitro. The AUC > Cmin of unchanged CDDP was found to be an important pharmacokinetic parameter predicting CDDP nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9137523     DOI: 10.1007/s002800050618

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  A mathematical model for cisplatin cellular pharmacodynamics.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

2.  Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas.

Authors:  Frank Kroschinsky; Denise Röllig; Barbara Riemer; Michael Kramer; Rainer Ordemann; Johannes Schetelig; Martin Bornhäuser; Gerhard Ehninger; Mathias Hänel
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-28       Impact factor: 4.553

3.  Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles.

Authors:  Xiang-Hong Peng; Yiqing Wang; Donghai Huang; Yuxiang Wang; Hyung Juc Shin; Zhengjia Chen; Michael B Spewak; Hui Mao; Xu Wang; Ying Wang; Zhuo Georgia Chen; Shuming Nie; Dong M Shin
Journal:  ACS Nano       Date:  2011-11-04       Impact factor: 15.881

4.  Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.

Authors:  K Hanada; K Odaka; A Kudo; H Ogata
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

5.  Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system.

Authors:  N Nishiyama; Y Kato; Y Sugiyama; K Kataoka
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

6.  Pharmacokinetics and toxicodynamics of oxaliplatin in rats: application of a toxicity factor to explain differences in the nephrotoxicity and myelosuppression induced by oxaliplatin and the other platinum antitumor derivatives.

Authors:  Kazuhiko Hanada; Makoto Suda; Norihito Kanai; Hiroyasu Ogata
Journal:  Pharm Res       Date:  2010-06-15       Impact factor: 4.200

Review 7.  [Radiotherapy, chemotherapy and target therapy for treatment of head and neck cancer : new developments].

Authors:  R Knecht
Journal:  HNO       Date:  2009-05       Impact factor: 1.284

8.  Cisplatin-induced hair cell loss in zebrafish (Danio rerio) lateral line.

Authors:  Henry C Ou; David W Raible; Edwin W Rubel
Journal:  Hear Res       Date:  2007-07-19       Impact factor: 3.208

9.  Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients.

Authors:  Mustafa E Ibrahim; Cara Chang; Yichun Hu; Susan L Hogan; Nickie Mercke; Madeleine Gomez; Cindy L O'Bryant; Daniel W Bowles; Blessy George; Xia Wen; Brian Buckley; Lauren Aleksunes; Melanie S Joy
Journal:  Eur J Clin Pharmacol       Date:  2018-09-15       Impact factor: 2.953

10.  Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients.

Authors:  F E de Jongh; R N van Veen; S J Veltman; R de Wit; M E L van der Burg; M J van den Bent; A S Th Planting; W J Graveland; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.